Table 1 Characteristics of patients from whom liver samples were obtained.
Sample | Sex | Age (Years) | BMI | Diabetes | Diagnosisa | Clinical feature |
|---|---|---|---|---|---|---|
PT#1 | M | 61 | 28.02 | U | Normal | |
PT#2 | M | 38 | 29.24 | N | Normal | |
PT#3 | M | 53 | 50.58 | N | Normal | |
PT#4 | F | 18 | 30.83 | N | Normal | |
PT#5 | F | 55 | 30.66 | N | Normal | |
PT#6 | M | 52 | 42.37 | Y | MASLD | 30% steatosis, no fibrosis, no cirrhosis, no necrosis |
PT#7 | M | 56 | 27.15 | N | MASLD | 50% steatosis (macrovesicular), no fibrosis, no cirrhosis, no necrosis |
PT#8 | M | 58 | 35.98 | N | MASLD | Severe steatosis |
PT#9 | M | 20 | 29.55 | N | MASLD | Severe steatosis |
PT#10 | M | 44 | 35.67 | Y | MASLD | 20% steatosis (macrovesicular) + Stage 1 fibrosis |
PT#11 | M | 20 | 35 | N | MASH | 80–90% steatosis (macrovesicular)+moderate periportal inflammation and focal active changes; necrosis present, no cirrhosis |
PT#12 | M | 42 | 30.6 | N | MASH | Steatohepatitis with >30% steatosis |
PT#13 | M | 65 | 43.81 | N | MASH | Steatohepatitis with 30% macrovesicular steatosis; mild portal inflammation |
PT#14 | M | 36 | 34.03 | N | MASH | Steatohepatitis with 30% macrovesicular steatosis+10% microvesicular steatosis; fibrosis (portal and bridging areas Stage 2–3) |
PT#15 | M | 46 | 23.4 | N | MASH | Steatohepatitis with 70% steatosis, ballooned hepatocytes, Mallory hyaline and lobular inflammation |
